AXS-14
Fibromyalgia
Phase 3Active
Key Facts
About Axsome Therapeutics
Axsome Therapeutics is a commercial-stage biopharmaceutical company dedicated to developing and commercializing novel therapies for central nervous system (CNS) disorders. Founded in 2012, the company has transitioned from a development-focused entity to a revenue-generating commercial organization with three FDA-approved products: Auvelity (AXS-05) for MDD, Sunosi for narcolepsy/OSA, and Symbravo for migraine. Its core strategy leverages a differentiated platform focused on synergistic drug combinations and novel formulations to address significant unmet needs in psychiatry, neurology, and pain, driving a market valuation exceeding $8 billion.
View full company profileTherapeutic Areas
Other Fibromyalgia Drugs
| Drug | Company | Phase |
|---|---|---|
| SP-104 | SCILEX | Preclinical/Phase 1 |
| Sequential Dialysis Technique | Halberd | Discovery |
| Stanza | Swing Therapeutics | Approved |
| Fibromyalgia Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| Fibromyalgia Biomarkers | Paradise Genomics | Discovery |
| SyqeAir Inhaler – Fibromyalgia | Syqe Medical | Commercial |
| SP-104 (low-dose naltrexone DR capsules) | Scilex Holding | Preclinical |